chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Fever, 103* chills (teeth were chattering) severe aches, dizziness, vomiting, abdominal pain, severe weakness.
I am currently lactating, and am 8 months postpartum at the time of the vaccine. Beginning immediately after, and continuing now for what has been just over 2 weeks, my milk supply has decreased by 15%. There are no other changes to my diet, exercise, medications, supplements, or life events that I can attribute to the change which coincides exactly with the date of my vaccination. Continued attempts to increase supply with additional water intake and pumping sessions has made no impact.
This spontaneous report as received from a nurse, refers to unspecified patients of unknown demography. No concurrent condition medical history or allergy/drug reactions were reported. On an unspecified date, since 02-JUN-2015, unspecified number of patients were vaccinated with improperly stored VAQTA injection (lot # K019560, expiration date: 02-JUN-2017) (strength, dose and route unspecified). No concomitant medication were reported. No adverse effect had been observed or reported. The outcome of the event was unknown. There were no product quality complaints (PQC) involved. No additional information was provided. This is one of several reports received from the same reporter. Follow up information has been received on 13-JUL-2015, that all telephone attempts to obtain follow-up information have been unsuccessful. Follow up information was received on 20-JUN-2015 with additional information on 21-JUN-2015. The patient was approximately 2 years old. The patient demographics were updates. On 04-JUN-2015 the patient was vaccinated with improperly stored VAQTA (lot # K019560, expiration date: 02-JUN-2017) (strength, dose and route unspecified). Additional information has been requested. Patient, suspect therapy and narrative were updated.
This case was reported by a consumer via call center representative and described the occurrence of tiredness in a 68-year-old male patient who received SHINGRIX for prophylaxis. Concomitant products included SHINGRIX. In October 2018, the patient received the 2nd dose of SHINGRIX. In October 2018, 2 days after receiving SHINGRIX, the patient experienced fever. On an unknown date, the patient experienced tiredness. Rechallenge with SHINGRIX was positive. In October 2018, the outcome of the fever was recovered/resolved. On an unknown date, the outcome of the tiredness was unknown. It was unknown if the reporter considered the tiredness and fever to be related to SHINGRIX. Additional details were provided as follows: This case was reported by the patient's wife. On 30th July 2018, the patient received 1st dose of SHINGRIX and felt slightly tired. The patient received 2nd dose of SHINGRIX about 2 weeks before the date of reporting. Less than a month after receiving SHINGRIX, the patient experienced tiredness but that worse than 1st dose and he had to go to bed for a day. He had a little fever on the 2nd day after administration. This case had been linked with case US2018201340, reported by same reporter for same patient.
Started feeling tired on 9/10, and fell asleep on the couch at a party.  Next moring, woke up with a rash under her left eye, which was dry and hurt.  The developed flu like symptoms; tired, congested, and medicine tried (Benadryl and Tylenol Cold) seemed to relieve symptoms.  PLEASE NOTE:  SHE ALSO HAD A FLU SHOT ON FRIDAY AS WELL.  Not sure which caused it; but she still has some effects from it 5 days later.
pt presented 9 days post vax w/fever, varicella rash on extremities, trunk, face
Large knot at injection site, redness, swelling,  itching, excessive tenderness  and soreness at injection site.
rash which would clear up and then reappear on different parts; pain at the injection site; redness at injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 5th April 2022, the patient received the 1st dose of Shingrix. On 5th April 2022, less than a day after receiving Shingrix, the patient experienced injection site pain. On 6th April 2022, the patient experienced injection site erythema. On 19th April 2022, the patient experienced rash. On an unknown date, the outcome of the injection site erythema and injection site pain were recovered/resolved and the outcome of the rash was not recovered/not resolved.   It was unknown if the reporter considered the injection site erythema, injection site pain and rash to be related to Shingrix.     Additional Information: GSK Receipt Date: 25-APR-2022 Reporter's Comment: Reporter was patient who called in to get more information on Shingrix side effects.  The patient received her first dose of Shingrix and that same day after vaccination she experienced some pain at the injection site which lasted 2 to 3 days and resolved.  The following day, the patient noticed redness at injection site and that lasted a week and had resolved.  Patient noted that 2 weeks post vaccination she began to develop a rash which would clear up and then reappear on different parts of her body.  She noted it appeared initially on her stomach, then behind her knee and now arm.  The rash had not resolved.  Provided medical advise disclaimer.  Provided info per package insert (PI) on side effects. The reporter consented to follow up.
Hours after my injection my arm was extremely sore; much worse than the first vaccination.  I could barely move it.  I got in the hot tub which did help a bit.  I didn't sleep well that night and kept waking up feeling achy and hot.  Around 6am my temperature was 101 degrees F, I felt fatigued, had body aches, and the area where I received the shot was very sore and a bit swollen, so  I took IBU 200 mg.  A couple hours later my temperature was 102 degrees, my fatigue and my body aches persisted , so I took another IBU 200mg.  Around noon I started to get what felt like a migraine but my temperature was back to normal so I took an Excedrin migraine.  My body aches, fatigue, and headache were resolving as the day went on although my arm was still very sore.  I was a bit fatigued the following day but much improved.  My arm soreness resolved after a few days.
Possible AE/  if they had COVID how much should she wait before receiving a booster; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Possible AE/  if they had COVID how much should she wait before receiving a booster) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Possible AE/  if they had COVID how much should she wait before receiving a booster). At the time of the report, COVID-19 (Possible AE/  if they had COVID how much should she wait before receiving a booster) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       CC: This is a spontaneous case concerning a female patient of unknown age with no reported medical history, who experienced the non-serious unexpected event of special interest COVID-19, after receiving unspecified dose of mRNA-1273. The benefit-risk relationship of mRNA-1273 is not affected by this report.  No Concomitant product use was reported. No treatment information was provided.  The patient wanted to know if they had COVID how much should they wait before receiving a booster dose.   Most recent FOLLOW-UP information incorporated above includes: On 29-Nov-2021: Follow-up received contains no new information.; Sender's Comments: This is a spontaneous case concerning a female patient of unknown age with no reported medical history, who experienced the non-serious unexpected event of special interest COVID-19, after receiving unspecified dose of mRNA-1273. The benefit-risk relationship of mRNA-1273 is not affected by this report.
Significant local reaction-Patient has 10cm red, swollen, painful, itching to the site and surrounding area
Information has been received from an office manager concerning a 16 year old female who on 21-DEC-2006 was vaccinated in the arm (unspecified) with the first dose of HPV vaccine (yeast). There was no concomitant medication. On approximately 21-DEC-2006, after receiving the vaccination, the patient developed a "knot" at the injection site. The patient sought unspecified medical attention. The "knot" at the patient's injection site persisted. Additional information has been requested.
I was given the GARDASIL shot. A week after being injected I had a serious allergic reaction and broke out in a very itchy rash all over my fingers and between fingers, and also spots on my face. The rash consisted of little bumps, and was spreadable.
THE NEXT MONRING AFTER THE SECOND SHOT, I WOKE UP AND WAS UNABLE TO HEAR OUT OF MY RIGHT EAR.  THE DAY BEFORE I WAS FINE AND ABLE TO HEAR.  WENT TO THE DOCTORS AND WAS TOLD POSSIBLE EAR INFECTION, GAVE ME STEROIDS, SUDEFED, CLARITAN MADE NO CHANGE. WENT THROUGH THIS TWICE WITH TWO DIFFFERNT DOCTORS AND THEY REFERRED ME TO A EAR NOSE AND THROAT SPECIALIST. WHO DID A HEARING TEST.
Mother reported that pt developed approx 50 cm round induration on left arm with redness and pain reported, area warm to touch, inflammation started 24 hours following immunization, area of induration was beginning to subside on 10/07/2005.
Left deltoid with swelling, redness and heat to touch. Referred to doctor. He ordered pain reliever and apply cold compress.
Pt was administered PNEUMOVAX 23 injection on 1/16/14. Pt called back to our office saying that the site was red and swollen, staff spoke with pt and advised pt to take BENADRYL and ice site as it was likely a local reaction. 1/17/14 staff called pt to report labs. Pt states that his arm was swollen from shoulder to elbow, tender, and red. I advised pt to come in today for Dr. to look at.
pt in for check up knot on leg @ site of inject cold compress first 24 hrs; then heat p/24 hrs lt thigh;  pt also exp rt thigh red & swollen, ice pack to thigh;
Admitted to Hospital  on 1/3/22 with c/o of fever, SOB, myalgia, headache, n/v, SOB, difficulty breathing x4 days.  Admitted and diagnosed with COVID 19, pneumonia, acute respiratory failure.  Reported to hospital that he had received Janseen COVID vaccine on 7/27/21, but information was not in state immunization system.  Expired at hospital on 1/14/22 from COVID 19 infection.
This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient. A female patient received bnt162b2 (BNT162B2), administration date 26Aug2021 (Batch/Lot number: unknown) as dose 1, single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEADACHE (non-serious) with onset 26Aug2021, outcome "unknown", described as "Headache". Additional information: It was reported that patient received the first dose of Pfizer Covid-19 vaccine on 26Aug2021 and experienced a bit of headache after receiving the vaccine. Asked if she can take Tylenol. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient states that he was dizzy and had nausea for 72 hours. He emailed his primary care doctor and is waiting for a response.
A headache woke me up and was with me all day with Tylenol alternating with Motrin.  Also had rapid heart rate that was also felt palpating with the throbbing headache.  No fever, cough, or body aches other than headache.
rapid heart rate, tongue swelling, severe headache, stomach issues, tired, bad taste in mouth, dry mouth, throat swelling, brain fog, diarrhea
SORENESS; VOMITING; TIREDNESS; NAUSEA; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022 expiry: UNKNOWN) dose, start therapy date were not reported for prophylactic vaccination. No concomitant medications were reported. On an unspecified date, the subject experienced soreness, vomiting, tiredness, and nausea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the soreness, tiredness, nausea and vomiting was not reported. This report was non-serious.
COVID-19 Vaccine is my worst enemy it causes a lot of health problem, causing a lot of heart problem; Vaccine need to work; I was forced to take poison; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CARDIAC DISORDER (non-serious), outcome "unknown", described as "COVID-19 Vaccine is my worst enemy it causes a lot of health problem, causing a lot of heart problem; Vaccine need to work; I was forced to take poison".  Additional information: As consumer was not willing to proceed the call and abruptly. Hence further probing could not be done. Limited information was available over the call.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
P/1st Hep vax experienced pruritic, pink, macular rash on her face & neck; Rash remitted slowly over the next 3days;
This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 46-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown. For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments. No concomitant medication reported. It was reported that the data logger that caller was unable to download were for the months of Dec-2021, Jan-2022, and Feb-2022. The reporter also stated that no adverse reactions were reported by any patients. No treatment medication details reported.
severe reaction; Initial information received on 22-Nov-2020 regarding an unsolicited valid non-serious social media case received from a consumer (Patient)..  This case involves a patient with unknown demographics, who had severe reaction (adverse reaction), while having received vaccine influenza vaccine.  The patient's medical history, past medical treatment(s), vaccination(s), family history and concurrent conditions were not provided.  Concomitant medications were not reported.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) (lot number, expiry date and other dosing details were not reported) for prophylactic vaccination  On an unknown date, (latency unknown, the patient had a severe reaction (adverse reaction) that sent the patient to bed for days, following the administration of INFLUENZA VACCINE.  Details of laboratory data not reported.  It was unknown if the patient received a corrective treatment.  The outcome of the event was unknown, at the time of this report.  There will be no information available on the batch number for this case.
Information has been received from a RN concerning a 30 year old female pt who was vaccinated with a first dose of varicella virus vaccine live. The pt developed chickenpox within 16 days of receiving the varicella virus vaccine. It was noted that the severity of the outbreak and details were not available at the time of this report.  Unspecified medical attention was sought. Additional information has been requested.
Child was standing by the check out counter when she started to fall backwards. She hit the back of her head on the wall as she fell. Pt. was reseen by Dr. and a blood preasure was take.
Information has been received from a physician concerning an approximately 12 month old male patient who on an unspecified date was vaccinated with a first dose of MMR II (Lot #, route and injection site not provided). The patient also received other concomitant vaccines (names and manufacturers unspecified). It was reported that the patient experienced a febrile seizure. At the time of this report, the patient had improved. It was unknown if the patient sought medical attention. Upon internal review, febrile seizure was considered to be an other important medical event. No further information is available.
laryngitis; This is a spontaneous report received from a contactable consumer (patient) via a Pfizer-sponsored program. A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiry date unknown), via an unspecified route of administration, on 21Jan2021, at single dose, for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. In 2021, the patient experienced laryngitis. She was prescribed with prednisone for it, but she has not taken it yet. She was wondering if it will change the efficacy of the vaccine. The outcome of the event was unknown.  Information about the lot/batch number has been requested.
48 hours later noted red patch at bandage site.  Mid injection point was clear.  Rash (fine red)- not uticaria spread to shoulder.  Pt taking laratadine and using topical cortisone.
nose started running; Chills; Left arm pain; Scratchy throat; This spontaneous case was reported by a consumer and describes the occurrence of THROAT IRRITATION (Scratchy throat), RHINORRHOEA (nose started running), CHILLS (Chills) and PAIN IN EXTREMITY (Left arm pain) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Feb-2021, the patient experienced THROAT IRRITATION (Scratchy throat). On an unknown date, the patient experienced RHINORRHOEA (nose started running), CHILLS (Chills) and PAIN IN EXTREMITY (Left arm pain). On 19-Feb-2021, THROAT IRRITATION (Scratchy throat) outcome was unknown. At the time of the report, RHINORRHOEA (nose started running), CHILLS (Chills) and PAIN IN EXTREMITY (Left arm pain) outcome was unknown.            Concomitant product use was not provided. Treatment information was not provided. Action taken with the mRNA-1273 in response to event is Not Applicable.
Immediately upon injection, tingling all over lasted for about less than 1 minute.  Within 20 minutes, tingling & facial muscle tightness around mouth.  Twitching & facial mouth muscle tightness for about 4 days, diminishing each day.  Vaccine was given Wed evening...finally Sun was little to none symptoms.
chills; T max 100 F; headache; Aches; fatigue; This is a spontaneous report received from contactable reporter(s) (Physician).  A 39 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administration date 20Feb2021 (Batch/Lot number: unknown) at the age of 39 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (dose 1, single , lot number: EL9262, intramuscular, administration time: 08:15), administration date: 25Jan2021, when the patient was 39 years old, for Covid-19 immunisation, reaction(s): "headache/ massive headache", "chills/ shivers", "Some fever 98.6/ temperature probably  went up to 98-99", "bodyaches", "sore arm". The following information was reported: CHILLS (non-serious), outcome "recovered", described as "chills"; BODY TEMPERATURE INCREASED (non-serious), outcome "recovered", described as "T max 100 F"; HEADACHE (non-serious), outcome "recovered", described as "headache"; PAIN (non-serious), outcome "recovered", described as "Aches"; FATIGUE (non-serious), outcome "recovered", described as "fatigue". The events "chills", "t max 100 f", "headache", "aches" and "fatigue" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of chills, body temperature increased, headache, pain, fatigue.  Additional Information: The vaccine was administered in a Public Health Department. It was reported that about 29 hours after vaccines symptoms/signs abated. The events did not result to emergency room visit.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Covid vaccine given after 24hr expiration, patient had no adverse reaction at that time. Nurse manager notified along with calling Pfizer for next step regarding if patient will need to be revaccinated.
first dose of COVID vaccine in 8 weeks ago & not possible to get second dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (first dose of COVID vaccine in 8 weeks ago & not possible to get second dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included No Adverse Events.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (first dose of COVID vaccine in 8 weeks ago & not possible to get second dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (first dose of COVID vaccine in 8 weeks ago & not possible to get second dose) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       there is no concomitant medications given in the treatment .   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: non significant followup
Developed shingles on left side of spine on mid/lower back area. 1.5 inch x .5 inch. I have a history of shingles in 2011.  I received the 2 dose shingles vaccine in 2019. I received my second Pfizer dose on 1/11. Developed fatigue and muscle aches on 1/12, then slight headache, muscle weakness, myalgia's and arthralgia  on 11/13.  Morning of 11/14, woke up and noticed a sore spot/blister on my lower/mid back area.  Slowly became more painful (burning sensation).  No injury to area or any other reason for blister and pain. 11/15, realized it was shingles.